United Therapeutics Corp

Insider buy of 9,500 UTHR shares by CEO Martine Rothblatt signals long‑term confidence in United Therapeutics’ pulmonary hypertension growth, balancing profit and position.

United Therapeutics CEO’s 10b5‑1 buy‑sell plan signals bullish confidence and long‑term commitment to the company’s pulmonary hypertension pipeline.

Insider buys signal confidence in United Therapeutics: CEO and EVP purchase shares under 10‑b‑5‑1 plan, suggesting a bullish outlook and potential upside as the company pursues its pipeline.

United Therapeutics CEO’s 10b5‑1 option exercise shows disciplined selling—little impact on stock, but worth tracking for investors.

Insider sale of 200 shares by Olian Judy D. at USTC shows routine rebalancing, not a bearish signal—investors can stay cautiously optimistic about United Therapeutics’ pipeline.

Discover why United Therapeutics’ leadership is buying and selling shares at strategic times—insider moves reveal confidence in a growing vascular therapy pipeline and solid long‑term upside.

Explore United Therapeutics’ insider trades: Paul Mahon’s 8,300‑share buy and strategic option sales reveal strong management alignment and a modest upside potential for UTHR investors.

United Therapeutics insider activity: CEO Benkowitz’s recent purchase signals long‑term confidence and potential upside for UTHR’s biotech pipeline.

Malcolm Jan’s recent 50‑share sale at United Therapeutics is a routine portfolio move, not a bearish signal—watch upcoming earnings for any shift.

Insightful UTHR insider trade recap: Paul Mahon’s February 2026 10(b)(5)(1) option exercise shows routine liquidity, not a warning. Read why it matters.